Loading clinical trials...
Loading clinical trials...
An Open Label, Phase 1, Pharmacokinetics, Maximal Usage Pharmacokinetics, Safety, and Efficacy Study of ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% Administered QD in Adolescent and Pediatric Subjects With Mild to Moderate Atopic Dermatitis
Conditions
Interventions
ARQ-151 cream 0.15%
ARQ-151 cream 0.05%
Locations
10
United States
Arcutis Clinical Site 07
Birmingham, Alabama, United States
Arcutis Clinical Site 11
Rancho Santa Margarita, California, United States
Arcutis Clinical Site 02
Coral Gables, Florida, United States
Arcutis Clinical Site 05
Hialeah, Florida, United States
Arcutis Clinical Site 13
Miami, Florida, United States
Arcutis Clinical Site 01
Mt. Pleasant, South Carolina, United States
Start Date
December 23, 2019
Primary Completion Date
May 2, 2023
Completion Date
May 2, 2023
Last Updated
July 24, 2023
NCT06850311
NCT07041892
NCT07121062
Lead Sponsor
Arcutis Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions